- Home
- IDYA vs TGI Comparison
IDYA vs TGI Comparison
Compare IDYA & TGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- TGI
- Stock Information
- Founded
- IDYA 2015
- TGI 1993
- Country
- IDYA United States
- TGI United States
- Employees
- IDYA N/A
- TGI N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- TGI Aerospace
- Sector
- IDYA Health Care
- TGI Industrials
- Exchange
- IDYA Nasdaq
- TGI Nasdaq
- Market Cap
- IDYA 1.9B
- TGI 2.0B
- IPO Year
- IDYA 2019
- TGI 1996
- Fundamental
- Price
- IDYA $24.27
- TGI $26.01
- Analyst Decision
- IDYA Strong Buy
- TGI Hold
- Analyst Count
- IDYA 13
- TGI 8
- Target Price
- IDYA $50.82
- TGI $20.63
- AVG Volume (30 Days)
- IDYA 1.0M
- TGI 1.3M
- Earning Date
- IDYA 08-05-2025
- TGI 08-06-2025
- Dividend Yield
- IDYA N/A
- TGI N/A
- EPS Growth
- IDYA N/A
- TGI N/A
- EPS
- IDYA N/A
- TGI 0.52
- Revenue
- IDYA $7,000,000.00
- TGI $1,261,962,000.00
- Revenue This Year
- IDYA $115.83
- TGI $9.20
- Revenue Next Year
- IDYA $252.50
- TGI $6.89
- P/E Ratio
- IDYA N/A
- TGI $49.59
- Revenue Growth
- IDYA N/A
- TGI 5.87
- 52 Week Low
- IDYA $13.45
- TGI $11.01
- 52 Week High
- IDYA $44.42
- TGI $26.03
- Technical
- Relative Strength Index (RSI)
- IDYA 63.79
- TGI 67.39
- Support Level
- IDYA $21.33
- TGI $25.82
- Resistance Level
- IDYA $25.54
- TGI $25.91
- Average True Range (ATR)
- IDYA 1.00
- TGI 0.06
- MACD
- IDYA 0.20
- TGI 0.00
- Stochastic Oscillator
- IDYA 70.60
- TGI 90.48
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About TGI Triumph Group Inc.
Triumph Group Inc designs and manufactures a broad portfolio of aerostructures, aircraft components, and systems for the aviation industry. It serves a customer base of players in the commercial, business, and military markets. The company operates under two operating segments: Systems and Support, which derives key revenue and designs, develops, and supports proprietary components; and Interiors, which supplies commercial and regional manufacturers with aircraft interior systems.